linjc16/ctgov huggingface dataset:
Retrospective Analysis for the ClotTriever Catheter to Investigate Safety and Effectiveness in the Treatment of Acute and Subacute Iliofemoral Deep Vein Thrombosis (DVT)

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to evaluate the safety and performance of the ClotTriever catheter in the treatment of patients with symptomatic iliofemoral deep vein thrombosis (DVT)

Detailed Description
-----------------
Data from patients in whom the ClotTriever catheter was used for treatment of iliofemoral DVT was retrospectively collected for up to 6 months after the procedure for evaluation of safety and effectiveness.

Official Title
-----------------
Retrospective Analysis for the ClotTriever Catheter to Investigate Safety and Effectiveness in the Treatment of Acute and Subacute Iliofemoral Deep Vein Thrombosis (DVT)

Conditions
-----------------
Deep Vein Thrombosis

Intervention / Treatment
-----------------
* Device: ClotTriever Catheter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: uni or bilateral iliofemoral DVT Exclusion Criteria: previously stented in treatment vein

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: ClotTriever Catheter|Treatment of iliofemoral deep vein thrombosis with the ClotTriever catheter|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Procedural success | Restauration of inflow in the treated vein | directly after treatment of the vein (Day 0) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of ClotTriever related major adverse events (MAE) | MAEs defined as death, major amputation or any clinically driven target lesion revascularisation | 1 month | 
| Number of lesions with at least Society Interventional Radiology (SIR) Grad II Lyse (50-95% thrombus removal) | Society Interventional Radiology (SIR) Grad II Lyse (50-95 % thrombus removal) or greater at the end of the procedure including adjunctive treatments | directly after treatment of the vein (Day 0) | 
| Vilallta score | Score for post thrombotic syndrome (PTS) assessing 5 subjective symptoms (pain, cramps, heaviness, paresthesia, pruritus) and 6 clinical signs (pretibial edema, skin induration, hyperpigmentation, redness, venous ectasia, pain on calf compression) with a 4-point scale from 0 (not present) to 3 (severe). | Day 0, month 1 and 6 | 
| Venous clinical severity score (VCSS) | Score of 10 parameters each assessed by severity 0-3. | Day 0, month 1 and 6 |
Spray Skin Treats for Pediatric Burns

Study Overview
=================
Brief Summary
-----------------
The treatment of burns in children remains a global challenge. At present, the clinical treatment plan is still waiting for further improvement. This study intends to retrospectively analyze the experience of treating children burn in recent years and promote sharing and application.

Detailed Description
-----------------
The treatment of burns in children remains a global challenge. Children's burn wounds have many characteristics that are different from those of adults, such as easy deepening of the wound, uncooperation in dressing change, poor resistance and so on. At present, there are new dressing applications a nd surgery in clinical treatment, etc., but how to treat children to achieve better therapeutic effects still needs to be explored. This study intends to retrospectively analyze the experience of treating children burn in recent years and promote sharing and application.

Official Title
-----------------
Spray Skin Treats in the Treatment of Pediatric Burns

Conditions
-----------------
Pediatric Burn

Intervention / Treatment
-----------------
* Procedure: spray skin
* Procedure: skin graft


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: burn for any reasons Children Exclusion Criteria: Combined with mental illness Congenital immune disease Severe cardiopulmonary failure，etc

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| experimental gourp<br>Autologous skin cell suspension combined with autologous skin graft was used to treat burn wound | Procedure: spray skin<br>* autologous skin cell suspension combined with skin graft<br>|
| Control group<br>Autologous skin graft was used to treat burn wound | Procedure: skin graft<br>* skin graft<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| take rate | take rate of skin graft | postoperative day 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complication rate | after skin grafting, skin infection, necrosis, subcutaneous hematoma, etc | through study completion, an average of 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pediatric burn, Spray skin, skin graft
Impact of the Stool Color Scale on the Detection of Neonatal Cholestasis

Study Overview
=================
Brief Summary
-----------------
The stool color scale was set in 2018 in the health books of French children. The study aim is to see if the scale is usefull for healthcare professionals and if this scale has advanced the detection of neonatal cholestasis.

Detailed Description
-----------------
The first part of the study consist in send a questionnaire to health professionnal to see their use of the stool color scale in the health book of newborn. The second part of the study is to see the age of children with cholestasis at the date of the first consult with a specialist.

Official Title
-----------------
Impact of the Stool Color Scale in the French Health Book on the Detection of Neonatal Cholestasis

Conditions
-----------------
Neonatal Cholestasis

Intervention / Treatment
-----------------
* Other: Stool color scale


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cholestasis Exclusion Criteria: -

Ages Eligible for Study
-----------------
Maximum Age: 12 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Stool color scale|observationnal trial about the use of the stool color scale by the health professionnals|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| use of stool color scale | questionnaire | 4 month |
LTFU Study of Subjects Who Received GRNOPC1

Study Overview
=================
Brief Summary
-----------------
This is a LTFU study for thoracic SCI subjects that were administered GRNOPC1 cells in the main study CP35A007.

Detailed Description
-----------------
Study CP35A008 is a Phase 1, multi-center long term follow-up (LTFU) study for five (5) subjects with complete thoracic SCI that were administered 2 million GRNOPC1 cells in the main study CP35A007. The purpose of this study is to monitor long-term safety in subjects for 15 years post GRNOPC1 administration.

Official Title
-----------------
Long Term Follow-up of Subjects Who Received GRNOPC1

Conditions
-----------------
Spinal Cord Injuries

Intervention / Treatment
-----------------
* Diagnostic Test: Magnetic Resonance Imaging (MRI)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects who received administration of GRNOPC1 under clinical study protocol CP35A007. Exclusion Criteria: There are no exclusion criteria for this LTFU study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Subjects treated with GRNOPC1 in the initial dosing study CP35A007<br>Subjects treated with GRNOPC1 in the initial dosing study CP35A007 will be followed for 15-year long-term safety monitoring | Diagnostic Test: Magnetic Resonance Imaging (MRI)<br>* Observational study; annual MRI for first 5 years only to monitor changes in the injection site<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence and severity of adverse events (AEs) | Information will be collected on all adverse events through Year 5 and on late-occurring adverse events (Years 6-15) related to any changes in neurological condition, a fever of unknown etiology, and the development of neoplasias and/or neurological disorders. | Up to 15 years after GRNOPC1 injection |
Diosmin as Adjuvant Therapy in Treatment of Non-bleeding Peptic Ulcer

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to evaluate the safety and efficacy of diosmin as adjuvant therapy in treatment of non-bleeding peptic ulcer patients.

Official Title
-----------------
Diosmin as Adjuvant Therapy in Treatment of Non-bleeding Peptic Ulcer

Conditions
-----------------
Non-bleeding Peptic Ulcer

Intervention / Treatment
-----------------
* Drug: Diosmin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -. Age 25-65 years old. Patients of both gender (male and female). Non-bleeding Peptic ulcer Patients (duodenal &gastric) diagnosed by endoscopy. Exclusion Criteria: The presence of other factors that can lead to gastric bleeding other than peptic ulcer. Patients with cancerous disease Breast-feeding. Surgically altered stomach ( bariatric surgery), Patient with liver disease. Bleeding & perforated peptic ulcer.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control group<br>this group will include 22 patients who will receive anti peptic ulcer only for 2 months. | |
| Active Comparator: Diosmin group<br>this group will include 22 patients who will receive anti peptic ulcer and diosmin 500 mg twice daily for 2 months. | Drug: Diosmin<br>* diosmin 500 mg twice daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| assesment of improvement of symptoms as indicated by change in SAGIS scale. | patients will undergo clinical assessment according to SAGIS scale at baseline and 2 months | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in Malondialdehyde (MDA) serum levels. | blood samples will be collected at baseline and 2 months. | 2 months | 
| change in Prostaglandin E2 (PGE2) serum levels. | blood samples will be collected at baseline and 2 months. | 2 months. | 
| change in Endothelin-1 (ET-1) serum levels. | blood samples will be collected at baseline and 2 months. | 2 months | 
| change in b-cell lymphoma 2(bcl-2) serum levels. | blood samples will be collected at baseline and 2 months. | 2 months |
Observation of Clozapine Treatment Safety in Bipolar Disorder.

Study Overview
=================
Brief Summary
-----------------
The purpose of the registry is to record incidence of adverse events during treatment with clozapine in patients suffering from bipolar disorder.

Detailed Description
-----------------
Bipolar disorder, with its spectrum, remains a life-long and significant mental health concern due to its unpredictable nature and varied symptomatology. Despite the wide array of available treatments, some cases of bipolar disorder remain resistant to traditional medications. Clozapine, traditionally used for treatment-resistant schizophrenia, has shown promising results in managing resistant cases of bipolar disorder, particularly reducing the risk of suicide. There are not enough controlled studies on clozapine, especially in treatment resistant bipolar depression. There are certain limitations associated with the use of clozapine, primarily related to the possibility of adverse events including agranulocytosis, myocarditis, pneumonia, intestinal obstruction and seizures. Therefore, there is a need for more studies on safety and tolerability of this treatment in patients with bipolar disorder.

Official Title
-----------------
Observation of Clozapine Treatment Safety in Bipolar Disorder.

Conditions
-----------------
Bipolar Disorder

Intervention / Treatment
-----------------
* Drug: Clozapine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of treatment-resistant depressive episode in the course of bipolar disorder according to DSM-5. Age from 18 to 65 years old. Exclusion Criteria: Patients unable to give fully written informed consent Patients unable to comply with the requirements

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients' name<br>Diagnosis of treatment-resistant depressive episode in the course of bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders-5. Age from 18 to 65 years old. | Drug: Clozapine<br>* Diagnosis of treatment-resistant depressive episode in the course of bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Age from 18 to 65 years old.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety measures of clozapine treatment in patients with bipolar disorder. | Incidence of possible occurrence of adverse events during treatment with clozapine in patients with bipolar disorder. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
clozapine, bipolar disorder, suicidality, adverse events
Application of Biomarkers in Neurological Diseases

Study Overview
=================
Brief Summary
-----------------
To explore the predictive and diagnostic role of biomarkers in patients with neurological diseases.

Detailed Description
-----------------
With the rise and continuous development of omics technology and bioinformatics technology, some scholars have applied proteomics technology and metabolomics technology to study the brain tissue, plasma and CSF of patients with nervous system diseases, so as to screen out potential biomarkers, with a view to providing new research ideas for pathogenesis and early diagnosis of neurological diseases. At present, the research on some novel biomarkers is still in its infancy, and many key problems remain to be solved. It is necessary to further determine the expression level of biomarkers in normal human body and the characteristics of biomarkers in patients with neurological diseases.

Official Title
-----------------
Application of Biomarkers in Neurological Diseases

Conditions
-----------------
Biomarkers

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with neurological diseases; Subjects or legal agents agree to participate in the study and sign the informed consent. Exclusion Criteria: Participating in other clinical investigators; Unwilling to be followed up or poor treatment compliance; Other conditions considered unsuitable for inclusion by the researchers.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients admitted to hospital/emergency department with neurological diseases<br>All clinical data, laboratory data and imaging data of patients at baseline and follow-up were collected, as well as blood and tissue samples that did not affect the diagnosis and treatment of patients after obtaining the consent of patients at different time points in the acute and chronic phases. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mRS score in 90 days | The proportion of 3-month good functional outcome (mRS Score 0-2) in patients with neurological diseases was evaluated by mRS Score | 3 months |
Gingival Depigmentation Using Diode Laser 940nm Versus 980nm

Study Overview
=================
Brief Summary
-----------------
is study aimed to evaluate the effectiveness of two diode lasers of different wave lengths 940nm and 980nm for the treatment of physiologic gingival melanin hyperpigmentation.

Official Title
-----------------
Gingival Depigmentation Using Diode Laser 940nm Versus 980nm: A Split-mouth Comparative Clinical Trial

Conditions
-----------------
Gingival Pigmentation

Intervention / Treatment
-----------------
* Device: Biolase Epic X 940nm wavelength Diode laser
* Device: Doctor smile simpler 980nm wavelength Diode laser


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients of both sexes diagnosed clinically with physiologic gingival pigmentation. Pigmentation extending from canine to canine in either upper or lower arch. Exclusion Criteria: Smokers. Patients with uncontrolled metabolic disease. Immuno-compromised patients. Patients with renal disease. Patients having coagulation disorders. Pregnant and lactating women. Evidence about the relation of pigmentation with malignancies. History of previous treatment of gingival pigmentation.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 940nm wavelength Diode laser<br> | Device: Biolase Epic X 940nm wavelength Diode laser<br>* Participants were treated with Biolase Epic X 940nm wavelength Diode laser set at a power of 1 W, fiber 400 µ, irradiation mode: pulsed wave (P3).<br>|
| Active Comparator: 980nm wavelength Diode laser<br> | Device: Doctor smile simpler 980nm wavelength Diode laser<br>* Participants were treated with doctor smile simpler 980nm wavelength Diode laser set at a power of 1 W, fiber 400 µ, irradiation mode: pulsed wave (SP).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intensity of pigmentation | Intensity of pigmentation was assessed with Dummett Oral Pigmentation Index (DOPI 1971). DOPI was scored as: Score 1: No clinical pigmentation (pink gingiva) Score 2: Mild clinical pigmentation (mild light brown color) Score 3: Moderate clinical pigmentation (medium brown or mixed pink and brown) Score 4: Heavy clinical pigmentation (deep brown or bluish black). | up to 12 weeks | 
| Extension of pigmentation | Extension of pigmented area was assessed by, Hedin Melanin Index (HMI). It was scored as: Degree 1: Isolated-only 1 or 2 pigmented interdental papillae Degree 2: Numerous pigmented interdental papillae Degree 3: Short continuous ribbons Degree 4: Long continuous ribbon | up to 12 weeks |
The Effect of Chiropractic Plus Nutritional Supplement in Patients With Chronic Pain and Inflammation.

Study Overview
=================
Brief Summary
-----------------
Evaluating the effect of a combined therapy of chiropractic sessions plus nutritional supplement containing hemp, omega-3 fatty acids, and broccoli extract oil in patients experiencing chronic pain and inflammation.

Official Title
-----------------
The Effect of Co-therapy Chiropractic Plus Nutritional Supplement in Patients Experiencing Chronic Pain and Inflammation.

Conditions
-----------------
Chronic Pain, Inflammatory Response

Intervention / Treatment
-----------------
* Dietary Supplement: Nutritional Supplement
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic pain (>3years) Exclusion Criteria: GABA/opioid medication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>Participants consume 1 serving of Placebo daily and attend weekly chiropractor sessions for 12 weeks. | Other: Placebo<br>* Placebo + Chiropractic sessions<br>* Other names: Chiropract sessions;|
| Experimental: Treatment Group<br>Participants consume 1 serving of the Nutrional supplement daily and attend weekly chiropractor sessions for 12 weeks. | Dietary Supplement: Nutritional Supplement<br>* Nutritional Supplement + Chiropract sessions<br>* Other names: Chiropract sessions;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in Pain level using the Brief Pain Inventory (BPI) after 12 weeks. | The BPI is a validated self-reporting instrument assessing pain. Possible score range 0-10 with higher scores indicating higher pain levels. The instrument contains 9 items. | Baseline and 12 weeks | 
| Change from baseline in Pain intensity using the 11-Point Numeric Rating Scale (11-NRS) after 12 weeks. | The 11-NRS is a validated self-reporting instrument assessing pain level. Possible score ranges from '0' representing no pain to '10' representing worst pain imaginable. | Baseline and 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reactive oxygen species (ROS) status | Reactive oxygen species (ROS) status in the peripheral blood mononuclear cells was used to assess participant's inflammation biomarkers. | At baseline and after 12 weeks |